retatrutide side effects clinical trials 2025 Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care Retatrutide Peptide for Weight Loss,

The impact of these differences on GSH remains to be elucidated

In clinical trials, Wegovy produced average weight loss of about 15% of body weight over 68 weeks, compared with roughly 5-8% for Contrave over 56 weeks

For example, miR-223-3p in LPS-stimulated extracellular vesicles (LPS-EVs) enhances Hippo signaling by targeting MEF2C, thereby promoting autophagy and ferroptosis in alveolar macrophages and aggravating S-ALI (Ye et al., 2025)

C.FaloneS.AimolaP.GiardinelliA.CasertaD.et al (2006)

Comparing the two: A breakdown of pros & cons To make an informed choice, its essential to look at a balanced comparison of these two categories